Oncopeptides News and Activities

Oncopeptides is a company listed under the stock ticker ONCO (SE).

View the org chart displaying its 14 main executives

Most searched biographies at Oncopeptides

• Sofia Heigis, Chief Executive Officer
• Per Samuelsson, Board Member
• Per Wold-Olsen, Chairman of the Board

Create your alert
to follow the executive moves at Oncopeptides.

Oncopeptides has 2,425 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Clearside Biomedical has gone out of its bankruptcy protection  (posted on July 15 2026).
• Attovia Therapeutics has filed its IPO. Its stock ticker will be ATTO. (posted on July 15 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 15 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Oncopeptides

• Number of shares and votes in Oncopeptides - Oncopeptides
• Oncopeptides submits Type II variation application to EMA for Pepaxti label expansion into third line treatment - Oncopeptides
• First patient enrolled in Oncopeptides’ glioblastoma study - Oncopeptides
• Sofia Heigis presented at Aktiespararna - Oncopeptides
• First patient enrolled in Oncopeptides’ real-world evidence study MARINA in Germany - Oncopeptides
• Oncopeptides to present clinical and translational data on Pepaxti at EHA 2026 in Stockholm - Oncopeptides
• Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe - Oncopeptides
• Bulletin from the Annual General Meeting in Oncopeptides - Oncopeptides
• Oncopeptides receives formal approval from Norwegian authorities to initiate Window-of-Opportunity study in glioblastoma - Oncopeptides
• Study confirms use of Pepaxti in a broader population, with strong data in the 50% of RRMM patients that suffer from reduced kidney function - Oncopeptides
• View more press releases Close

Social media about Oncopeptides

• Oncopeptides on Wikipedia, Google News & Yahoo Finance
• Oncopeptides on LinkedIn, X (Twitter) & YouTube